

## **Response to Review (BMC Infectious Diseases)**

Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: A community-based longitudinal seroprevalence survey on COVID-19 (K-SEROSMART Wave 2)

### **Comments to the Author**

**1.** Please clarify whether the questionnaire/interview/survey used in your study was developed for this study or has previously been published elsewhere. If the questionnaire/interview/survey has been published elsewhere, please provide a reference to it in your manuscript. If the questionnaire/interview/survey was developed for this study, please upload an English language version as a supplementary file and cite it in your main manuscript.

**Response:** Thank you for your comment. The questionnaire was specifically developed for K-SEROSMART, and an English language version of the questionnaire has been included as a supplementary material. This has been appropriately cited in the main manuscript.

**Correction:** Methods section- Measurement- Paragraph 1 (lines 106-107) and Supplementary Material 1

**2.** Authors reporting experiments on humans and/or the use of human tissue samples must confirm that all experiments were performed in accordance with relevant guidelines and regulations. Please ensure that a statement to confirm this has been included in the “Ethics approval and consent to participate” section.

**Response:** Thank you for your valuable comment. We have ensured that the required statement, confirming that all experiments involving humans and/or human tissue samples were conducted in accordance with relevant guidelines and regulations, is included in the “Ethics approval and consent to participate” section. This updated statement now explicitly indicates compliance with ethical standards and relevant regulations.

**Correction:** Methods section- Ethics approval and consent to participate - Paragraph 1 (lines 202-203)